Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

S. 2624: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Funding for FDA - FY 2025 Appropriations
FY 2025 President's Budget Request
Inflation Reduction Act of 2022 (P.L. 117-169)
2025 LHHS

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Executive Office of the President (EOP), Office of Management & Budget (OMB), Congressional Budget Office (CBO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
Artificial Intelligence (AI)
Bayh-Dole Act
March-In Rights
Compulsory Licensing - 28 USC 1948 Government Use of Patents
Coronavirus (COVID-19) Pandemic - TRIPS Waiver
S.79/H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023
S. 113: Prescription Pricing for the People Act of 2023
S. 148 Stop STALLING Act
S. 150: Affordable Prescriptions for Patients Act of 2023
S. 3583/H.R. 6986: A bill to address patent thickets
Restrictions on Intellectual Property Rights
S. 2220/H.R. 4370: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act
Patent Litigation Reform
Patenting of Biological Inventions - Section 101 Modernization
H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues
H.R. 6986: To address patent thickets - Provisions related to patents
S. 3583: A bill to address patent thickets

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Commerce - Dept of (DOC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

340B Drug Discount Program - 340B Accountability Act
340B Drug Discount Program - Program Implementation & Oversight
340B Drug Discount Program - PROTECT 340B Act
340B Drug Discount Program - RFI for SUSTAIN 340B Act
H.R. 2408: Access to Innovative Treatments Act of 2023
Artificial Intelligence (AI)
Accelerated Approval
Alternative Funding Programs
Drug Shortages
Supply Chain Integrity and Traceability
Drug Patenting
S. 79/H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023
S. 113: Prescription Pricing for the People Act of 2023
S. 148: Stop STALLING Act
S. 150: Affordable Prescriptions for Patients Act of 2023
CMMI Aurthority
COVID-19 Pricing Related Provisions
Implementation of the Inflation Reduction Act (IRA) of 2022
PBM Reform
Funding for FDA - FY 2024 Appropriations
Funding for FDA - FY 2025 Appropriations
S. 127: Pharmacy Benefit Manager Transparency Act of 2023
S. 2973: Modernizing and Ensuring PBM Accountability (MEPA) Act
Alternative Payment Arrangements for Gene Therapies
Coverage of Accelerated Approval Products
Drug Benefit Design
Value-Based Purchasing (VBP) Rule
Orphan Drug Issues
H.R. 5539/S. 3131: ORPHAN Cures Act
H.R. 6664: Innovation in Pediatric Drugs Act of 2023
S. 1214: Retaining Access and Restoring Exclusivity (RARE) Act
Implementation of the Inflation Reduction Act (IRA) of 2022
Reimbursement and Coverage of Innovative Products
H.R. 830/S. 1375: HELP Copays Act
H.R. 2408: Access to Innovative Treatments Act of 2023
H.R. 2139/S. 909: Prescription Drug Price Relief Act
H.R. 2630/S. 652: SAFE STEP Act
H.R. 2666: Medicaid for VBPs for Patients (MVP) Act
H.R. 4895: Lowering Drug Costs for American Families Act
H.R. 5378: Lower Costs, More Transparency Act
CMMI Authority
Lower Costs, More Cures Act
Medicare Part B Physician-Administered Products
National Coverage Determination
Patient Cost-Sharing and Smoothing
Step Therapy
Support of Patient Premiums and Cost-Sharing Obligations
Value-based Contracting and Communications
Value-Based Purchasing (VBP) Rule
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program
H.R. 456: Fairness in Orphan Drug Exclusivity Act
H.R. 2408: Access to Innovative Treatments Act of 2023
H.R. 2679: Pharmacy Benefits Manager Accountability Act
H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act
H.R. 2880: Protecting Patients Against PBM Abuses Act
H.R. 3093: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
H.R. 3285: Fairness for Patient Medications Act
H.R. 3433: Give Kids a Chance Act of 2023
H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing
H.R. 5376: Share the Savings with Seniors Act
S. 476/H.R. 5547: Maintaining Investments in New Innovation Act
H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act
H.R. 6664: Innovation in Pediatric Drugs Act of 2023
H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs
S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs
S. 1264: SMART Prices Act - Provisions related to drug pricing reform
S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs
S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs
S. 1906: Promising Pathway Act - Approval pathway policy issues
S. 1967: PBM Act
S. 2456: Protecting Seniors from High Drug Costs Act
S. 2474: Share the Savings with Seniors Act
S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA)
S. 4953: Protect Drug Innovation Act
User fee policy issues
Pharmacy Benefit Manager reform and policy issues
Drug cost and pricing policy issues
Drug importation policy issues
Accelerated approval authority policy issues
FDA regulatory approval authority policy issues
Competition policy issues
Clinical trial diversity policy issues
Patient assistance program policy issues
Drug shortages policy issues
COVID-19 policy issues
Pandemic preparedness policy issues
Artificial intelligence policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Congressional Budget Office (CBO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

340 Drug Discount Program
340B Accountability Act
PROTECT 340B Act
RFI for SUSTAIN 340B Act
Drug Pricing - FY 2024 Appropriations
Drug Pricing - FY 2025 Appropriations
H.R. 2139/S. 908: Medicare Drug Price Negotiation Act
H.R. 2148/S. 909: Prescription Drug Price Negotiation Act
H.R. 4895: Lowering Drug Costs for American Families Act
H.R. 5539: ORPHAN Cures Act
H.R. 6283: DRUG Act
S. 476/H.R. 5547: Maintaining Investments in New Innovation Act
H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act
S. 79/H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023
S. 113: Prescription Pricing for the People Act of 2023
S. 127: Pharmacy Benefit Manager Transparency Act of 2023
S. 142: Preserve Access to Affordable Generics and Biosimilars Act
S. 148: Stop STALLING Act
PBM Reform
Medicaid
H.R. 2666: The Medicaid VBPs for Patients (MVP) Act
Average Manufacturers Price Calculations
Coverage of Accelerated Approval Products
Drug Benefit Design
Medicaid Drug Rebate Program Rule
Pricing and Rebates
Value-Based Purchasing (VBP) Rule
Reimbursement and Coverage of Innovative Products
H.R. 830/S. 1375: HELP Copays Act
H.R. 2139/S. 908: Medicare Drug Price Negotiation Act
H.R. 2148/S. 909: Prescription Drug Price Relief Act
H.R. 2408: Access to Innovative Treatments Act of 2023
H.R. 2630/S. 652: SAFE STEP Act
H.R. 4895: Lowering Drug Costs, More Transparency Act
CMMI Authority
Implementation of the Inflation Reduction Act (IRA)
In-Home Administration of Part B Drugs
Lower Costs, More Cures Act
National Coverage Determination
Protected Classes
Step Therapy
Support of Patient Premiums and Cost-Sharing Obligations
Value-Based Purchasing (VBP) Rule
H.R. 3421: Medicare for All Act
Inflation Reduction Act of 2022 (P.L. 117-169)
Part D redesign and policy issues including non-interference and rebates policy issues
Part B policy issues
Drug cost and pricing policy issues
Rebate policy issues
Value-based purchasing arrangements policy issues
Center for Medicare and Medicaid Innovation (CMMI) and model policy issues
CMS Guidance on the Medicare Drug Price Negotiation Program: Initial Memorandum
CMS Medicare Drug Price Negotiation Revised Guidance

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Congressional Budget Office (CBO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Taxation/Internal Revenue Code
Research & Development Tax Credit Reforms
H.R. 7024: Tax Relief for American Families and Workers Act of 2024
S. 866: American Innovation and Jobs Act
Foreign Direct Investment

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Expensing of R&D Expenditures
Foreign Drug Data Protection Laws
H.R. 4307: Medical Supply Chain Resiliency Act
S. 1834/H.R. 3858: No Free TRIPS Act
S. 845: Short on Competition Act
S. 2115: Medical Supply Chain Resiliency Act
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Supply chain policy issues
WTO TRIPS waiver policy issues
China outbound investment policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. Trade Representative (USTR), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), State - Dept of (DOS), U.S. Agency for International Development (USAID), Health & Human Services - Dept of (HHS), White House Office, Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Anti-Trust Reform

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes